Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)121.25
  • Today's Change-8.65 / -6.66%
  • Shares traded260.62k
  • 1 Year change+132.15%
  • Beta1.0491
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

  • Revenue in USD (TTM)133.48m
  • Net income in USD42.14m
  • Incorporated1987
  • Employees58.00
  • Location
    Ligand Pharmaceuticals Inc3911 Sorrento Valley Blvd, Suite 110SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 550-7500
  • Fax+1 (302) 636-5454
  • Websitehttps://www.ligand.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tilray Brands Inc812.04m-212.62m1.35bn2.65k--0.375--1.66-0.2746-0.27461.033.970.18752.318.73306,429.10-4.64---5.15--29.42---24.78--1.57-1.160.0953--25.80--83.14------
Avadel Pharmaceuticals PLC (ADR)95.15m-106.22m1.53bn154.00--21.82--16.13-1.17-1.171.040.73060.53080.69415.41617,850.60-59.26-40.21-80.97-47.9994.62---111.64-374.752.52-10.250.00-----22.99-16.59------
Ocular Therapeutix Inc61.10m-138.36m1.73bn267.00--4.57--28.33-1.09-1.090.52492.430.1912.362.12228,827.70-43.26-46.70-47.93-54.1890.8489.36-226.46-228.6516.55-11.300.1509--13.4996.60-13.65--26.37--
Immunocore Holdings PLC - ADR281.45m-53.44m1.74bn497.00--4.83--6.17-1.07-1.075.557.180.35560.56795.56566,303.60-6.75-27.55-8.35-36.8299.41---18.99-97.125.15--0.5495--43.0551.23-5.22--2.85--
Harrow Inc154.15m-33.58m1.86bn315.00--31.83--12.09-0.9508-0.95084.381.650.5814.954.39489,352.40-12.66-10.86-14.77-12.7171.1670.75-21.78-15.352.43-0.35180.7608--46.9525.77-73.30--143.88--
Tarsus Pharmaceuticals Inc83.37m-150.07m1.88bn244.00--7.45--22.55-4.43-4.432.436.630.2947--5.36341,696.70-53.05-31.56-60.10-33.8292.50---180.00-242.596.99--0.221---32.42---118.86--279.39--
Endo Inc-100.00bn-100.00bn1.93bn3.00k--1.05----------23.99------------------------1.52--0.5697---13.25--15.87------
Supernus Pharmaceuticals Inc651.97m59.71m2.02bn652.0034.272.0114.143.101.071.0711.7118.240.49620.96894.54999,957.104.544.955.836.4189.0488.619.1612.841.98--0.00---8.958.24-97.83-58.81-8.17--
Harmony Biosciences Holdings Inc681.88m122.63m2.06bn246.0017.083.4514.013.022.112.1111.7510.460.799424.269.172,771,866.0014.387.4617.129.0878.6580.5817.9810.463.20--0.23450.0032.93---28.99---25.31--
Ligand Pharmaceuticals Inc133.48m42.14m2.22bn58.0054.502.8328.6616.602.222.227.3342.820.16430.47894.082,301,345.005.1912.325.3512.9991.8281.6531.5780.3215.81--0.00002---33.09-12.181,131.21-17.8642.63--
Amphastar Pharmaceuticals Inc712.89m166.52m2.34bn1.76k15.393.3210.643.283.143.1413.4514.570.49682.856.04404,821.7011.719.4213.5411.5654.6847.8323.5615.232.637.420.45150.0029.1416.9450.51---4.00--
Vericel Corp214.52m789.00k2.65bn314.002,855.6310.86445.8812.340.01890.01894.464.970.6244.414.97683,184.700.2295-3.070.2595-3.5070.4267.870.3678-4.494.16--0.0008--20.1716.8080.96--59.35--
Twist Bioscience Corp295.21m-220.31m2.66bn919.00--5.41--9.01-3.81-3.815.128.390.40765.428.56321,229.60-30.42-30.50-33.85-33.8440.5336.02-74.63-113.334.52--0.00--20.4157.336.08--49.76--
Amneal Pharmaceuticals Inc2.60bn-174.62m2.70bn7.70k----29.361.04-0.6224-0.622410.09-0.18570.72063.003.60337,401.60-3.69-4.80-4.93-5.9335.0434.76-5.13-9.000.81651.241.00--8.207.5635.38---6.55--
Catalyst Pharmaceuticals Inc460.48m142.80m2.85bn167.0020.424.3215.836.201.171.173.785.540.7774.348.662,757,377.0024.1025.4227.9429.8186.3285.6331.0130.874.92--0.000.0085.90280.39-14.05--20.21--
Data as of Nov 08 2024. Currency figures normalised to Ligand Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

54.83%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 20242.63m14.40%
The Vanguard Group, Inc.as of 30 Jun 20241.90m10.38%
Janus Henderson Investors US LLCas of 30 Jun 20241.00m5.48%
Macquarie Investment Management Business Trustas of 30 Sep 2024887.28k4.86%
SSgA Funds Management, Inc.as of 30 Jun 2024688.77k3.77%
Dimensional Fund Advisors LPas of 30 Sep 2024669.41k3.66%
Stephens Investment Management Group LLCas of 30 Sep 2024618.70k3.39%
Congress Asset Management Co. LLPas of 30 Sep 2024604.04k3.31%
Chicago Capital LLCas of 30 Sep 2024545.82k2.99%
St. Denis J. Villere & Co. LLCas of 30 Sep 2024474.86k2.60%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.